MedTrace Logo

Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy

NCT00403325 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2008-11-03

No results posted yet for this study

Summary

The purpose of this study is to examine the effects of Lucentis for active Central Serous Chorioretinopathy.

Conditions

  • Central Serous Chorioretinopathy

Interventions

DRUG

rhuFab V2 [ranibizumab] ( Lucentis )

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Vitreous -Retina- Macula Consultants of New York

    lead OTHER

Principal Investigators

  • Richard F. Spaide, M.D. · Vitreous Retina Macula Consultants of New York, P.C.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00403325 on ClinicalTrials.gov